

Original Research Article

High prevalence of isolated hepatitis B core antibody among adults in Oyo State, Nigeria: the need for review of diagnostic and vaccination guidelines

ABSTRACT

Background: Ten years of neonatal immunization with hepatitis B (HB) vaccine has not had any significant effect on the prevalence of the disease in Nigeria.

Aim: To investigate hepatitis B virus (HBV) markers as potential risk factors for viral transmission.

Study design: A pilot prevalence study.

Place and Duration of Study: Community centers in Ibadan and Ogbomosho, between July 2014 and September 2014.

Methodology: One hundred and ninety-two apparently healthy volunteers (61 men, 131 women: age range 11-88 years) were investigated for HBV serological/immunological markers using enzyme linked immunoassays with 99 - 99.7% and 98.4 - 100% for specificity and sensitivity respectively (Diagnostic Automation/Cortez Diagnostics, Inc., Calabasas, CA, USA). Also data were processed with the statistical package for the social sciences version 20.0 (SPSS Inc., USA).

Results: A prevalence of 22.9%, 14.6%, 19.3%, 90%, 53.6%, 6.8% and 22.9% was obtained for HBsAg, HBsAb, HBcAb-IgM, HBcAb-Total, isolated HBcAb, HBeAg, and HBeAb, respectively. Analysis of the lifetime exposure of 90% among participants showed that 44 and 103 have markers for present (HBsAg) and past (isolated HBcAb) infections respectively, while 26 recovered with evidence of surface antigen neutralizing antibodies (HBsAb) in their serum. Seropositivity for HBsAg was highest among males and the 21-30 years old, while the female gender and persons aged 31-40 accounted for the largest percentage of isolated HBcAb carriers. Although history of exposure to risk factors like scarification, tattooing, injection from unqualified healthcare practitioners, surgery, blood transfusion, sharing of sharp instrument/tools and injection drug use was common among participants, only 15.6% took hepatitis B immunization. On the overall, the risk of HBV infection was significantly associated with scarification, tattooing, and sharing of sharp instrument and tools.

Conclusion: The study highlights potential risk associated with the current diagnostic

guideline for hepatitis B status and advocates the need for immunization among susceptible unvaccinated population.

Keywords: Hepatitis B virus, Isolated HBcAb, Adult Population, High Prevalence, Nigeria.

1. INTRODUCTION

Hepatitis B (HB) is a life-threatening infection of the liver, ranked by the World Health Organization as one of the most common and serious infectious disease worldwide. Presently three quarters of the world's population live in highly endemic areas, while about 2 billion are estimated to be infected [1]. Therefore the global disease burden of hepatitis B is substantial. Every year, there are over 4 million acute cases and about 25% of carriers, while 1 million people die from chronic active hepatitis, cirrhosis or primary liver cancer [1]. Hepatitis B is highly endemic in developing countries of Southern Asia and Tropical Africa, where at least 8% of the populations are chronic carriers and 70-90% becomes infected before the age of 40, showing past or present serological evidence of hepatitis B virus (HBV) infection. Although most infections occur in children with little evidence of acute disease related to HB, the rates of chronic liver disease and liver cancers in adults are high [2].

The virus is transmitted majorly by exposure to infectious body fluids and sexual intercourse, while risk factors include medical/dental/surgical procedures, living with an infected person, multiple sex partners, reuse of needles and syringes, tattooing, risky sexual activities, and sharps contaminated with infected blood as well as working in healthcare facilities [3]. Hepatitis B is a vaccine preventable disease, and about 85-90% of HBV-associated death can be prevented, when given before or shortly after exposure. However, in spite of the availability of safe and effective vaccine for an upward of 20 years, worldwide infection persists [1]. Nigeria has adopted the universal neonatal vaccination through the expanded programme on immunization (EPI) and had utilized a monovalent HB vaccine since 2004. This was replaced by the pentavalent vaccine administered in 3 doses commencing at the age of 6 weeks on neonates free of charge. Despite this continuous immunization exercise, the prevalence of HBV infection among Nigerians has remained high. Hence it becomes important to assess the population for viral factors with potential for the spread of the disease.

Immunity to HBV develops only in persons who are vaccinated or exposed to transient infection. Therefore, the prevalence of hepatitis B surface antigen (HBsAg) alone may be an underestimation of the current HB status in any population. Although most publications from Nigeria investigated the surface antigen prevalence [4-7]; data from other parts of the world have shown that this is not sufficient to predict latent infections. The recovery of HBV for many years in the blood of infected persons following clinical recovery and the induction of HBV-specific antibodies and cytotoxic T lymphocytes corroborated this fact [8]. Also HBV transmissions have been reported from surface antigen negative but hepatitis B core antibody (HBcAb) positive healthy individuals under various circumstances [9-12]. Therefore, HBsAg seronegativity does not exclude the existence of HBV DNA in the blood and liver tissue of individuals with previous exposure to the virus. In this study, we have investigated a cohort of apparently healthy individuals for HBV markers. This is necessary to generate data to propose recommendations for limiting the spread and reducing the prevalence of the disease in the nearest future.

2. MATERIAL AND METHODS

2.1. Study Population

Public educational programs were organized bi-monthly at the community centers to give information on HBV disease, risk factors, prevention, and control to participants. The study was conducted for 3 months (July - September 2014) in two cities (Ogbomosho and Ibadan) in Oyo State, Nigeria. However only consenting participants (older than 10 years) who were apparently healthy, with unknown HB status and have not had hepatitis B related symptom in the past were recruited for this study.

2.1.1. Data collection

Relevant information describing the demography, as well as past and present behavioural risks and exposure was obtained from recruited individuals. These include age, sex, occupation, marital status, scarification, transfusion, surgery, tattooing, indiscriminate injection from unprofessional healthcare practitioners, drug abuse, multiple sex partners, sharing of sharp objects, and HB immunization status.

2.1.2. Sample collection

Three millilitres (3 mL) of venous blood specimen was collected from each participant. Samples were kept in upright position at room temperature for 45 minutes to allow clotting. Samples were spun for 15 minutes at 1,500 rpm at 4°C. The supernatant (sera) were aliquoted in 0.5 mL labelled cryovials and stored at -40°C until used.

2.2. Sample Analysis

Assessment of recruited persons for HBV markers was done using some sets of antigen-antibody systems. These are the: the surface antigen-antibody system (HBsAg, HBsAb), envelope antigen-antibody system (HBeAg, HBeAb), core antibody system (HBcAb-IgM, HBcAb-Total). ELISA kits were used according to the manufacturer's instructions (Diagnostic Automation/Cortez Diagnostic Inc., Calabasas, California, USA).

2.2.1. Detection of HBsAg and HBeAg

The analysis uses an antibody sandwich ELISA technique in which polystyrene microwell plates were pre-coated with monoclonal antibodies specific to HBsAg. Fifty microliters (50 µl) of test sera were added to plates together with 50 µl of a second antibody conjugated to the enzyme horse radish peroxidase (HRP-conjugate) directed against a different epitope of HBsAg. The incubation at 37°C for 60 minutes allowed the formation of a specific immunocomplex which was captured on a solid phase. After washing 5 times with diluted wash buffer, chromogen solution containing tetramethyl benzidine (50 µl) and urea peroxide (50 µl) were added to the wells and was followed by incubation at 37°C for 15mins in the dark. The enzymatic reaction between the chromogen solutions and the HRP-conjugate produces blue coloured product in HBsAg positive wells. Finally intense yellow colour developed in positive wells following the addition of 50 µl stop solution. Absorbances were read with a dual filter reader at 450nm/630nm, and specimen giving an absorbance equal to or greater than the cut-off value was considered reactive.

2.2.2. Detection of HBsAb

The kit employed an antigen sandwich ELISA technique with recombinant HBsAg pre-coated on polystyrene microwells. Test sera (50 µl) and the horse radish peroxidase-conjugate (50 µl) were then added to labelled wells and plates incubated at 37°C for 60mins. The presence of anti-HBs initiated the binding of pre-coated and conjugated antigens to the two variable domains of the antibody, to form a specific immunocomplex captured on the solid phase during incubation. Following the removal of unbound HRP-conjugates by washing, 100 µl of

chromogen solutions were added to the wells. The chromogens were hydrolysed by the bound HRP-conjugate during incubation for 15mins at 37°C in the dark to a blue coloured product which turned yellow after stopping the reaction with 50 µl sulphuric acid. Colour intensity was read at 450nm/630nm and specimens with values greater than or equal to the cut-off are considered reactive.

2.2.3. Detection of HBcAb IgM

The principle of the HbcAb IgM ELISA was based on two-step incubation, solid phase antibody capture ELISA. To polystyrene microwells pre-coated with antibodies intended for human immunoglobulin M proteins were added 100 µl of test sera and were incubated at 37°C for 30 min. This was followed by washing to remove IgG-class antibodies and other sample components. The specific anti-HBc IgM captured on the solid phase was then identified by the addition of purified HBcAg which is marked with anti-HBc monoclonal antibody conjugated to HRP. At the time of second incubation (37°C for 30 min), the HRP-conjugated antigens reacted with anti-HBc IgM antibodies. Then, 100 µl of chromogen solutions were added after washing, and the content of the well reactive to HBcAb IgM turned from blue to yellow by the addition of a stop solution. Plates were read with a dual filter at 450nm/630nm and values greater than or equal to the cut-off were positive.

2.2.4. Detection of total HBcAb and HBeAb

The ELISA test used is based on the solid phase, competitive assay with one step incubation. Test sera were added to plates and incubated at 37°C for 60 min. During incubation, the antibody present in the test sera competed with monoclonal antibodies conjugated to HRP for a fixed amount of purified antigen pre-coated in the wells. Plates were washed, followed by the addition of 100 µl chromogens which turned blue when the colourless chromogens were hydrolysed by the bound HRP-conjugate. Reaction was stopped with 50 µl of the stop solution to give a yellow colouration. Absorbance's were read with a dual filter instrument, and values less than or equal to the cut-off were considered positive.

2.3. Data Analysis

The data collected and ELISA results on HBV markers were processed with the statistical package for the social sciences Version 20.0 (SPSS Inc., USA) while a test of significance was calculated using Chi-Square at 95% confidence interval and $P = .05$ was considered significant.

3. RESULTS

3.1. Demographic characteristics of participants

During the 3-month study period from July to September 2014, 192 consented volunteers were recruited for this pilot study. Participants included 31.8% (61) males and 68.2% (131) females. The larger number of women in attendance at the educational programs was responsible for the inclusion of more women in the study. Also 125 persons (65.1%) were married, while 45 (23.4%) had more than one sex partner (Table 1). Recruited individuals were evenly spread through the 21-30, 31-40 and 41-50 age groups with 49, 56 and 44 individuals respectively, while the >11-20 and >50 years had 22 and 21.

The analysis of past exposure to risk factors showed that 51% and 16.1% had scarification and tattooing on their bodies, while 17.2% and 16.7% had undergone surgical procedure and took blood transfusion respectively (Table 1). Although sharing of sharp objects like knives, razor, etc. was a common practice and reported by 140 (72.9%) participants, only 65 (33.9%) took injection indiscriminately, while 8 participants (4.2%) reported administration of unknown injectable provided by friends a few times. On the overall, only 30 (15.6%) participants took preventive HB vaccine.

160 **Table1: Demography and exposure to risk factors among apparently healthy**
 161 **participants in Ibadan and Ogbomosho, Oyo State, Nigeria**

162

Variable	Total participants	Percentage
Demography		
Age categories		
>11-20	22	11.5
21-30	49	25.5
31-40	56	29.2
41-50	44	22.9
>50	21	10.9
Sex		
Female	131	68.2
Male	61	31.8
Risk factors		
Scarification	98	51.0
Blood transfusion	32	16.7
Tattooing	31	16.1
Surgery	33	17.2
Injection from unqualified		
Healthcare workers	65	33.9
Multiple sex partner	45	23.4
Injection drug use	8	4.2
Sharing of sharps	140	72.9

163

164 **3.2. Detection of HBV markers**

165 A total of 44 (22.9%) participants positive for HBsAg consisted of 37 and 7 acute
 166 (HBcAbIgM+) and chronic infections respectively. The prevalence for HBSAg was higher
 167 among males (54.5%) while the 21-30 years category accounted for 36.4% of infected
 168 persons (Table 1). However HBsAg detection rate was lowest at the two extreme age
 169 categories representing 11.4% and 4.5% for 11-20 and >50 age groups respectively. Core
 170 antibody (HBcAbTotal) was found in 173 (90%) with 103 (53.6 %) representing isolated anti-
 171 HBc. The protective immunity to HBV (anti-HBs) was present only in 28 (14.6%) individuals;
 172 while a total of 17 (8.9%) had no serologic marker for HBV. Further investigation of hepatitis

B status showed that 13 of the HBsAg positive cases were highly infectious; being HBeAg reactive, while 27 had seroconverted with anti-HBe in their blood. In addition, 10 participants with isolated anti-HBc and 7 with HBsAb were reactive for anti-HBe (Table 3).

Table 2: Distribution of Hepatitis B markers among apparently healthy participants in Ibadan and Ogbomosho, Oyo State, Nigeria

Variable	Total	HBsAg- HBcAb+ HBsAb+	HBsAg- HBcAb+ HBsAb-	HBsAg- HBcAb- HBsAb+	HBsAg+ HBcAb- HBsAb-	HBsAg+ HBcAb+ HBsAb-	HBsAg- HBcAb- HBsAb-
Number	192	26	103	2	1	43	17
studied	(100%)	(13.5%)	(53.6%)	(1.04%)	(0.52%)	(22.4%)	(9%)
Sex							
Female	131	22 (84.6%)	76 (73.8%)	1 (50%)	1 (100%)	19 (44.2%)	12 (70.6%)
	(68.2%)						
Male	61	4 (15.4%)	27 (26.2%)	1 (50%)		24 (55.8%)	5 (29.4%)
	(31.8%)						
Age groups (years)							
> 11-20	22	1 (3.8%)	11 (10.7%)	1 (50%)		5 (11.6%)	4 (23.5%)
	(11.5%)						
21-30	49	4 (15.4%)	24 (23.3%)			16 (37.2%)	5 (29.4%)
	(25.5%)						
31-40	56	11 (42.3%)	28 (27.2%)	1 (50%)	1 (100%)	13 (30.2%)	2 (11.8%)
	(29.2%)						
41-50	44	7	26			7	4

	(22.9%)	(26.9%)	(25.2%)	(16.3%)	(23.5%)
> 50	21	3	14	2	2
	(10.9%)	(11.5%)	(13.6%)	(4.7%)	(11.8%)

Table 3: Prevalence of HBeAg and HBeAb among apparently healthy participants in Ibadan and Ogbomosho, Oyo State, Nigeria

Variable	HBsAg+	HBsAb+	Isolated HBcAb	Total
HBeAg+	13	0	0	13
HBeAb+	27	7	10	44
Total	40	7	10	57

3.3. Risk factors associated with HBV positivity

One hundred and forty-seven (76.6%) individuals were presently seropositive for HBV infection without the neutralizing surface antibodies (HBsAb), this consists of 44 for current infection (HBsAg+) and 103 for past infection (isolated HBcAb+) (Table 4). The sex distribution of prevalence of 96 and 51 for female and male, respectively, was not statistically significant ($P = .86$), while the seropositive individuals were found in all age groups. The association of other risk factors with infection was determined. It was observed that the risks of infection was higher among individuals sharing sharp instruments ($P = .01$ and $.02$), those with tattoo ($P = .00$), and scarification ($P = .047$). However, blood transfusion, indiscriminate injection from unqualified healthcare workers, previous surgery, multiple sex partners, and injection drug use were not significantly associated with HBsAg and HBcAb seropositivity.

196 **Table 4: Hepatitis B infection and risk factors among apparently healthy participants**
 197 **in Ibadan and Ogbomosho, Oyo State, Nigeria**
 198

Variable	Total Tested (N=192)	HBsAg positive (n=44)	Isolated HBcAb (n=103)	Total HBV positive markers (n=147)	HBsAg (<i>P</i> - value)	Isolated HBcAb (<i>P</i> - value)
Sex						.86
Female	131	20	76	96		
Male	61	24	27	51		
Age group (years)					.19	.37
>11-20	22	5	11	16		
21-30	49	16	24	40		
31-40	56	14	28	42		
41-50	44	7	26	33		
>50	21	2	14	16		
Exposure to risky procedure and behaviours						
Scarification					.85	.047
Yes	98	23	62	85		
No	94	21	41	62		
Blood transfusion					.13	.39
Yes	32	4	23	27		
No	160	40	80	120		
Tattooing					.00	.62
Yes	31	1	21	22		
No	161	43	82	125		
Surgery					.87	.37
Yes	33	8	21	29		

No	158	36	82	118		
Injection from quacks					.08	.91
Yes	65	10	41	51		
No	127	34	62	96		
Injection drug use					.06	.33
Yes	8	4	3	7		
No	184	40	100	140		
Multiple sex partners					.49	.35
Yes	45	12	25	37		
No	147	32	78	110		
Sharing of sharps instrument/tools					.01	.02
Yes	140	25	80	105		
No	52	19	23	42		
History of HB immunization					.32	.37
Yes	30	9	14	23		
No	162	35	89	124		

199

200

201 4. Discussion

202

203 The pilot study investigated the prevalence of HBV markers among apparently healthy
 204 individuals in two largest cities of Oyo state (Ibadan and Ogbomosho), with a view to provide
 205 potential evidence for viral factors in the unabated transmission of HBV in spite of over 10
 206 years of neonatal immunization. This is necessary to generate data to appropriately target
 207 prevention/control measure for individuals born before the nationwide implementation of HB
 208 vaccine in the EPI in Nigeria in 2004.

209 An overall prevalence of 22.9% (44/192) was observed for active hepatitis B infection among
 210 participants. The seroprevalence of 22.9% is consistent with previous reports from Nigeria
 211 [4-7]. The reported prevalence ranges from 10.3% - 44.7%, depending on the sampling
 212 population. However, it was found to be much lower than the prevalence's among people
 213 living with HIV in Gombe (26.5%), chronic liver disease patients at a Nigerian Teaching
 214 Hospital (40%), primary school children in a rural community in Borno state (44.7% [4-5, 7].
 215 The reason for this large difference might be because the surveys involved high risk groups.
 216 Although the number of male participants was lower than that of the females (61 vs. 131),
 217 the HBsAg seropositivity was higher among male participants (54.5% vs. 45.5%). Similar
 218 reports independent of the prevailing risk factors and degree of endemicity have been
 219 documented in populations randomly sampled for HBsAg seroprevalence [7, 13-14]. The

higher prevalence among the males has been attributed to the fast clearance of HBsAg in women [15]. Hepatitis B surface antigen carriage was found to increase with age and by 40 years; consequently, 79% have been infected. This according to El Beltagy *et al* (2008) may have been due to potential exposure over a long period of time, the non-immunization status of the older population as well as the lack of information on HBV infection and transmission in the past decades [16].

A lifetime exposure of 90% (HBcAb-Total) for HBV positivity due to past or present exposure was observed. This is in agreement with Alter (2002) that there could be 70-90% serological evidence of HBV exposure among populace in the highly endemic regions of South East Asia, sub-Saharan African and the Amazon Basin [2]. Similar studies reported 43.9% and 72.4% in China and Uganda respectively [17-18]. The endemicity of HB was revealed in the exposure pattern. This increase with age and by 50 years, 86.4% of the participants was infected.

Reports from several studies have implicated several risk factors in the transmission and acquisition of HBV. These include low educational level, used needles and syringes, family history of hepatitis B, scarification, dental procedure, sexually transmitted infections, sharing of multiple sex partners and lack of immunization with HB vaccine [7, 16, 19-20]. However, tattooing, percutaneous injection drug use and high-risk sexual activity have accounted for most cases of newly acquired HB in the developed countries [21-23].

In the present study, sharing of sharp instruments was significantly associated with the prevalence of HbsAg ($P = .01$) and HBcAb ($P = .02$), while tattooing and scarification have P -values of .00 and 0.047 for HBsAg and HBcAb respectively. Scarification has been an age long cultural practice among various tribes in Africa for defining identity, beauty, strength, and rites of passage. This is usually done by traditional practitioners using blades and knives soaked in cleansing liquids. However, this practice has been identified as a significant factor in the spread of HBV in the region [7, 24-25]. Tattooing on the other hand is imported from the western culture and has been recognized and documented widely as an important factor in the transmission of HBV as well as association with epidemic outbreak in the past [21, 26-27]. In several instances, this was due to unhygienic tattooing procedures, illicitly performed by untrained individuals using unsterile and frequently shared equipment [27]. However the association between tattooing and risk of HBV infection was higher among populations involved in high-risk behaviours. The recent popularity of tattooing among younger adults deemed it necessary for intensive prevention programs for this group, while enforcement of a large scale infection control measures is important for the interruption of transmission. Sharing of sharp instruments and tools was found to be highly correlated with the prevalence of HBsAg and HBcAb in this study. These include grooming items (razor, toothbrushes, and shaving/hair clippers) as well as tools for daily work tasks; they can serve as effective inanimate vehicles especially during percutaneous exposure to source positive for HBeAg. Instrument and tool sharing is a common practice within households and work places and has been documented as a significant source of HBV transmission [24, 28].

Fifty-four percent (103/192) of the participants had isolated HBcAb. The prevalence of 54% is higher than previous report from Nigeria [29-30]. This may not be unconnected with the fact that the present study included a wider population range compared to the cohorts of blood donors and HIV patients on ART in previous studies. The presence of isolated HBcAb has been an issue of great concern with regard to HBV transmission. Often it represents a remote resolved infection, a low-level chronic infection, or the presence of a "window phase" between the disappearance of HBsAg and the appearance of HBsAb [31]. The potential for active hepatitis B infection in isolated HBcAb was demonstrated by HBV transmission from blood and organ donors who had isolated HBcAb [9-12]. Several studies from India, a developing country endemic for HBV infection documented HBV DNA detection (12.4% - 27.2%) in persons with isolated anti-HBc [32-34]. This poses a great risk to recipients of blood products and organs from anti-HBc individuals. Also these HBsAg seronegative DNA carriers are at risk for HB reactivation, following immunosuppressive therapy. In the light of

the above, therefore, anti-core screening should be implemented in the screening guideline for blood/organ donation as well as HB diagnosis in Nigeria. A decline in new infection of HBV occurred in several endemic countries following the introduction of anti-core screening [31, 35-36] while nucleic acid testing (NAT) was recently implemented in low prevalence countries (Ireland, 2002; Germany, 2002; Canada, 2005). According to Pereira (2003) and Jackson *et al* (2003), this had a small health benefit in the European Union and the USA at a very high cost relative to other blood safety measure. However it has been predicted that there would be greater benefit in countries with high HB prevalence [37-38]. Therefore participants with isolated HBcAb in this study shall be investigated further using HBV vaccination and HBV DNA testing to rule out chronic infection. However those found infected would be referred for appropriate treatment and follow-up.

Although only 15.6% of the participants were vaccinated, vaccination appears not to be a significant factor in disease prevention ($P = .05$). The result from this study showed that only 6.7% (2/30) of the vaccinees had protective immunity. This is highly suggestive of incomplete vaccination, although the study failed to include the number of HB vaccine doses taken in the data collection. The incidence of HB in the developed countries has been reduced greatly by active infant vaccination, while a more comprehensive and established infrastructure for vaccine delivery to adolescents and adults has been implemented with considerable success in the USA [39-40]. Hence, the need for increased public awareness campaign for vaccination and possibly vaccine availability free of charge for adults in Nigeria. This as a suggested strategy for combating HBV spread caters for the adult population as they enter into the ages of greatest incidence of infection.

5. CONCLUSION

This study highlights potential risk associated with the current diagnostic guideline for HB status and advocates the need for adult population vaccination. Vaccination is the most effective strategy to halt HBV infection and until aggressive vaccination of the adults is embarked upon, the risk for hepatitis B infection and associated chronic liver diseases will continue unabated for many years to come.

LIMITATIONS OF THE STUDY

Although, the sample size of 384 was calculated, this was halved due to the financial implication of the ELISA kits used for analysis.

ETHICAL APPROVAL

The study was approved by the University of Ibadan/University College Hospital ethics committee and its participants provided written or oral informed consent.

REFERENCES

1. World Health Organization. Hepatitis B: Emergencies preparedness, response. 2015a. Accessed 8 July 2015. Available: <http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html>.

- 318 2. Alter M. Epidemiology of hepatitis B in Europe and worldwide. *J Hepatol.*
319 2003;39:S64–9.
- 320 3. World Health Organization. Hepatitis B Fact sheet N 204. 2015b. Accessed 12 July
321 2015. Available: <http://www.who.int/mediacentre/factsheets/fs204/en/>.
- 322 4. Mustapha SK, Jibrin YB. The Prevalence of hepatitis B surface antigenemia in
323 patients with Human Immunodeficiency Virus infection in Gombe, Nigeria. *Ann Afr*
324 *Med.* 2004;4:10-12.
- 325 5. Bukbuk DN, Bassi AP, Mangoro ZM. Sero-prevalence of hepatitis B surface antigen
326 among primary school pupils in rural Hawal valley, Borno State, Nigeria. *J*
327 *Community Med Primary Health Care.* 2005;17(1):20-3.
- 328 6. Onuzulike N, Ogueri EO. Sero-prevalence of hepatitis B surface antigen in pregnant
329 women in Owerri, Imo State of Nigeria. *Res J Bio Sci.* 2007;2(2):178-82.
- 330 7. Omuemu CE, Ndububa DA, Nnabuchi CV. Prevalence of hepatitis B surface antigen
331 and anti-hepatitis C antibodies in chronic liver disease patients in a Nigerian
332 Teaching Hospital. *J Med Res Practice.* 2012;1(2). Accessed 14 July 2015.
333 Available: <http://www.journalmanagers.com/index.php/jmrp/article/view/19>.
- 334 8. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for
335 decades after patients' recovery from acute viral hepatitis despite active
336 maintenance of a cytotoxic T-lymphocyte response. *Nat Med.* 1996;2: 1104-08.
- 337 9. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of
338 transplantation-associated de novo hepatitis B infection in the liver transplant
339 recipient. *Liver Transpl Surg.* 1997;3:105-11.
- 340 10. Dickson RE, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH *et al.*
341 Transmission of hepatitis B by transplantation of livers from donors positive for
342 antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive
343 Kidney Diseases Liver Transplantation database. *Gastroenterology.* 1997;113:1668-
344 74.
- 345 11. Gow PJ, Mutimer DJ. De novo hepatitis B infection acquired during liver
346 transplantation. *QJM.* 2001;94:271-75.
- 347 12. isolated hepatitis B core antibody in blood donors from Sao Paulo. *Rev Inst Med*
348 *Trop Sao Paulo.* 2001;43:203-08.
- 349 13. Amidu N, Alhassan A, Obirikorang C, Feglo P, Majeed SF, Timmy-Donkoh E. *et al.*
350 Sero-prevalence of hepatitis B surface antigen in three densely populated
351 communities in Kumasi, Ghana. *J Med Biomed Sci.* 2012;1(2):59-65.
- 352 14. Andoulo FA, Tagni-Sartre M, Dominique NN, Djapa R, Ndam ECN. Prevalence of
353 hepatitis B surface antigen in a population of workers in Cameroon. *Open Journal of*
354 *Gastroenterology.* 2013;3:323-27.
- 355 15. Sharma SK, Saini N, Chwla Y..(2005) Hepatitis B virus: inactive carriers. *Virol J.*
356 2005;2:82. doi:10.1186/1743-422X-2-82.
- 357 16. EL Beltagy KE, Al Balawi IA, Almuneef M, Memish ZA. Prevalence of hepatitis B
358 virus markers among blood donors in a tertiary hospital in Tabuk, NorthWestern,
359 Saudi Arabia. *Int J Infet Dis.* 2008;12(5):495-99.
- 360 17. Ochola E, Ocamo P, Orach CG, Nankinga ZK, Kalyango JU, McFarland W. *et al.*
361 2013) High burden of hepatitis B infection in Northern Uganda: results of a
362 population-based survey. *BMC Public Health.* 2013;13:727. doi: 10.1186/1471-
363 2458-13-727
- 364 18. Ji Z, Wang T, Shao Z, Huang D, Wang A, Guo Z. *et al.* A population-based study
365 examining hepatitis B virus infection and immunization rates in Northwest China.
366 *PLoS ONE.* 2014;9(5):e97474. doi:10.1371/journal.pone.0097474.
- 367 19. Awadalla HI, Ragab MH, Osman MA, Nassar NA. Risk factors of viral hepatitis B
368 among Egyptian blood donors. *Br J Med Med Res.* 2011;1(1):7-13.
- 369 20. Mboto CI, Edet EJ. Prevalence and risk factors of hepatitis B virus infection among
370 students in University of Uyo. *Int J Modern Bio Med.* 2012;2(2):101-11.

- 371 21. Spada E, Mele A, Ciccozzi M, Tosti ME, Bianco E, Szklo A. *et al.* Changing
372 epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis
373 surveillance system in Italy. *Digest Liver Dis.* 2001;33:778-84.
- 374 22. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K *et al.*
375 Incidence and risk factors for acute hepatitis B in the United States, 1982-1998:
376 implications for vaccination programs. *J Infect Dis.* 2002;185(6):713-9.
- 377 23. Boulos D, Goedhuis NJ, Wu J, Baptiste B, Poliquin D, Furseth J *et al.* Enhanced
378 surveillance for acute and likely acute hepatitis B in Canada: 1999 to 2002. *Can J*
379 *Infect Dis Med Microbiol.* 2005;16(5):275-81.
- 380 24. Nwokediuko S. (2009) Risk Factors for hepatitis B virus transmission in Nigerians: a
381 case-control study. *The Internet Journal of Gastroenterology.* 2009;10(1). Accessed
382 14 July 2015. Available: ispub.com/IJGE/10/1/11182.
- 383 25. Ben-Alaya-Bouafif N, Bahri O, Chlif S, Bettaieb J, Toumi A, Bel Haj HN. *et al.*
384 Heterogeneity of hepatitis B transmission in Tunisia: risk factors for infection and
385 chronic carriage before the introduction of a universal vaccine program. *Vaccine.*
386 2010;28(19):3301-07.
- 387 26. Rosario Pac M, Arnedo A, Montaner MD, Prieto P, Garcia J, Izuel M. *et al.* (1996)
388 Epidemic outbreak of hepatitis B from tattoo in gypsy families. *Rev Esp Salud*
389 *Publica.* 1996;70(1):63-9.
- 390 27. Viswanathan U, Beaumont A, O'Moore E, Ramsay M, Tedder R, Ijaz S. *et al.*
391 Hepatitis B transmission-event in an English prison and the importance of
392 immunization. *J Public Health.* 2010;33(2):193-96.
- 393 28. Nwokediuko S, Ijoma U. Relatively high seroprevalence of hepatitis B surface
394 antigen in female civil servants in Enugu State of Nigeria. *EuroAsian journal of*
395 *Hepato-Gastroenterology.* 2011;1(1):19-22.
- 396 29. Jeremiah ZA, Idris H, Ajayi BB, Ezimah AC, Malah MB, Baba MM. Isolated anti-HBc-
397 IgM antibody among blood donors in the semi- arid region of Nigeria. *Human*
398 *Antibodies.* 2011;20(3-4):7-82. doi: 10.3233/HAB-2011-0242.
- 399 30. Oluyinka OO, Atiba A, Oluremi AS, Ojo J, Odewale G. Prevalence of anti-HBc in HIV
400 patients on ART in Ekiti, Nigeria. *International Journal of Tropical Disease and*
401 *Health.* 2015;8(2):75-8.
- 402 31. Busch MD. Prevention of hepatitis B, hepatitis C and human immunodeficiency virus
403 infections through blood transfusion by anti-HBc testing. *Vox Sang.* 1998;74(2):147-
404 54
- 405 32. Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic screening of
406 blood donors in India reveals a lack of correlation between anti-Hbc titer and PCR-
407 amplified HBV DNA. *Transfusion.* 2003;43:1442-48.
- 408 33. Banerjee A, Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S. *et al.*
409 Frequency and significance of hepatitis B virus surface gene variant circulating
410 among 'antiHBc only' individuals in Eastern India. *J Clin Virol.* 2007;40:312-17.
- 411 34. Asim M, Ali R, Khan LA, Husain SA, Singla R, Kar P. Significance of anti-HBc
412 screening of blood donors and its association with occult hepatitis B virus infection:
413 implications for blood transfusion. *Indian J Med Res.* 2010;132:312-17.
- 414 35. Japanese Red Cross non-A, non-B Hepatitis Research Group. Effect of screening
415 for hepatitis C virus and hepatitis B virus core antibody on incidence of post-
416 transfusion hepatitis. *Lancet.* 1991;338:1040-41.
- 417 36. Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR. *et al.*
418 Donor screening for antibody to hepatitis B core antigen and hepatitis B virus
419 infection in transfusion recipients. *Transfusion.* 1995;35(1):5-12.
- 420 37. Pereira A. Health and economic impact of post-transfusion hepatitis B and cost-
421 effectiveness analysis of expanded HBV testing protocols of blood donors: a study
422 focused on the European Union. *Transfusion.* 2003;43:192-201.

423 38. Jackson BR, Busch MP, Stramer S, AuBuchon JP. The cost-effectiveness of NAT
424 for HIV, HCV and HBV in whole blood donations. *Transfusion*. 2003;43:721-29.
425 39. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. *Int J*
426 *Med Sci*. 2005;2(1): 20-23.
427 40. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L. *et al*. 2006) A
428 comprehensive immunization strategy to eliminate transmission of hepatitis B virus
429 infection in the United States. *MMWR*. 2006;55(RR16):1-25.
430
431
432
433
434
435
436
437
438